Guardant Health Partners with Pfizer to Showcase Tumor Classification Advances
Guardant Health (GH) announced the company and its research collaborators will present 38 abstracts, as well as one oral presentation in partnership with Pfizer (PFE), showcasing advances in methylation-based tumor classification and liquid biopsy technology at the American Society of Clinical Oncology Annual Meeting in Chicago, Illinois taking place May 29 - June 2, 2026. Key data that will be presented include: Abstract #3077 validating the use of Guardant360 Liquid CDx as a companion diagnostic for therapy selection and comprehensive pan-cancer tumor profiling in routine oncology practice. Findings led to recent FDA approval of the IVD assay, demonstrating how incorporating both genomic and epigenomic signals for variant detection produces strong analytical sensitivity, accuracy, and specificity across clinically relevant alterations. Abstract #3070 revealing the potential of Guardant360 Liquid in expanding access to targeted ALK inhibitor therapy and getting the right treatment to lung patients faster. Abstract #TPS10632 evaluating longitudinal performance of the Shield blood test for primary colorectal cancer screening in its intended use population, building off the strong performance in the prospective, observational ECLIPSE study that led to FDA approval.
